Detailed company information
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 23, 2026
Earnings Transcript for 2026 - Q1Released: Apr 30, 2026
Earnings Transcript for 2025 - Q4Released: Feb 26, 2026
Earnings Transcript for 2025 - Q3Released: Oct 30, 2025
Earnings Transcript for 2025 - Q2Released: Jul 25, 2025
Earnings Transcript for 2025 - Q1Released: Apr 24, 2025
Earnings Transcript for 2024 - Q4Released: Feb 27, 2025
Earnings Transcript for 2024 - Q3Released: Oct 30, 2024
Earnings Transcript for 2024 - Q2Released: Jul 25, 2024
Earnings Transcript for 2024 - Q1Released: May 02, 2024
Earnings Transcript for 2023 - Q4Released: Feb 22, 2024
Earnings Transcript for 2023 - Q3Released: Oct 26, 2023
Earnings Transcript for 2023 - Q2Released: Jul 27, 2023
Earnings Transcript for 2023 - Q1Released: May 04, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Oct 27, 2022
Earnings Transcript for 2022 - Q2Released: Jul 28, 2022
Earnings Transcript for 2022 - Q1Released: Apr 28, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 29, 2021
Earnings Transcript for 2021 - Q1Released: Apr 29, 2021
Earnings Transcript for 2020 - Q4Released: Feb 25, 2021
Earnings Transcript for 2020 - Q3Released: Oct 29, 2020
NovoCure's 2026 revenue is projected to remain primarily driven by Optune Gio, with growing contributions from newly launched Optune Pax and expanding Optune Lua markets. This analysis breaks down the expected revenue distribution and growth trajectories across these key products.
Read post
Dafinchi
